Embed Size (px)
Citation preview
Faculty of Chemistry Belgrade 2011.Faculty of Chemistry Belgrade 2011.
Supported by
Faculty of Chemistry, University of BelgradeInstitute for Biological Research ”Siniša Stanković”University of Belgrade
Serbian Biochemical SocietyPresident: Mihajlo B. SpasićVice-President: Karmen Stankov General Secretary: Marija Gavrović-Jankulović Treasurer: Milan Nikolić
Committee
Đorđe Fira Ivanka KaradžićJelena Kotur-StevuljevićOlgica Nedić Snežana MarkovićGordana StojanovićMaja Živković
Advisory Board
Gordana Grubor-LajšićGordana MatićVesna Niketić
Proceedings
Edited by: Mihaјlo SpasićTechnical secretary: Jelena NestorovCover and logo design: Aleksandra Nikolić - KokićPublisher: Faculty of Chemistry, Serbian Biochemical SocietyPrinted by: Colorgrafx, Belgrade
Serbian Biochemical Society
First Conference
University of Belgrade, Faculty of Chemistry.15.11.2011. Belgrade, Serbia.
“Towards co-operation and integrated research”
Coinciding with the 100-year anniversary of The Biochemical Society (UK)
PROGRAM
10.00-10.10 Welcome message from the President of the Serbian Biochemical Society Prof. M. B. Spasić.
10.15-10.45 David R. Jones, PhD Inositide Laboratory, Paterson Institute for Cancer Research, University of Manchester, UK
Signalling networks in cancer.
10.45-10.50 Discussion
10.50-11.00 Pause
11.00-11.20 Marija Gavrović-Jankulović, PhD Department of Biochemistry, Faculty of Chemistry, University of Belgrade, Belgrade, Serbia
Immediate hypersensitivity: Molecular and immunological features of allergens.
11.20-11.40 Djordje Miljković, PhD Department of Immunology, Institute for Biological Research “Siniša Stanković” University of Belgrade, Belgrade, Serbia
Neuroinflammation: From rat to man.
11.40-12.00 Ivan Spasojević, PhD Institute for Multidisciplinary Research, University of Belgrade, Belgrade, Serbia Iron chelation: Way to hell and back.
12.00-12.15 Discussion
12.15-12.30 Pause
12.30-12.50 Duško Blagojević, PhD Department of Physiology, Institute for Biological Research “Siniša Stanković” University of Belgrade, Belgrade, Serbia
Molecular mechanisms of redox signalling in homeostasis, adaptations and pathology; hypothermia.
12.50-13.10 Snežana Dragović, PhD Department of Radioecology and Agricultural Chemistry, Institute for the Application of Nuclear Energy – INEP, University of Belgrade,Belgrade,Serbia
Biomonitoring for human and environmental health: Current status and perspectives in radioecology.
13.10-13.30 Snežana Marković, PhD Institute of Biology and Ecology, Faculty of Science, Kragujevac, Serbia
The effects of nitric oxide donors and the other bioactive substances on the energy and oxidative-antioxidative metabolism of blood cells and cancer cell lines.
13.30-13.45 Discussion
13.45-14.20 Pause /Cocktail
14.20-14.40 Karmen Stankov, MD, PhDClinical center of Vojvodina, Medical Faculty Novi Sad, Serbia
Mitochondrial redox metabolism in oxyphilic thyroid cancer
14.40-15.00 Jelena Bašić, MD, PhD Institute of Biochemistry, Medical Faculty, University of Niš, Serbia.
Matrix metalloproteinase-9, TNF alpha- and TNF receptor gene polymorphisms in juvenile idiopathic arthritis
15.00 Discussion and CONCLUDING REMARKS
Foreword
Dear colleagues,It is my great pleasure to warmly welcome you to the first conference
entitled “Towards co-operation and integrated research” organized by the Serbian Biochemical Society.
The first Biochemical Society in the world was established in the UK in 1911. The Biochemistry Section of the Serbian Chemical Society was established in 1967. The Biochemical Society of the Socialist Republic of Serbia was active from 1976 to 1991. In 1997 the Yugoslav Biochemical Society was registered (Niketic 2010). Today’s Serbian Biochemical Society was recently registered on the 5th of July 2011. Prof. Israel Pecht, the FEBS president, announced in a letter dated the 25th of August 2011 that the FEBS Council had accepted that the Serbian Biochemical Society should replace the Yugoslav Biochemical Society thereby becoming a full FEBS member.
The Serbian Biochemical Society clearly has deep roots, but this is officially its first conference. Its aim is to stimulate collaborative research work for many years to come. This year, 2011, coincides with the centennial anniversary of the UK Biochemical Society. Therefore, we have invited one lecturer from the UK and eight from Serbia to present their research interests. Their presentations are published in the conference proceedings. This first conference serves as an initiative to organize future annual scientific conferences in Serbia in order to present high quality work in fast moving research fields and to improve scientific interactions in the field of biochemistry and other disciplines of life sciences. I express my gratitude to the members of the governing board of the Serbian Biochemical Society who suggested the lecturers and to all of them who accepted their invitation.
ReferencesVesna Niketić: BIOHEMIJSKO DRUŠTVO SRBIJE. Knjiga:
SRPSKA HEMIJSKA NAUČNO-STRUČNA DRUŠTVA: Prilog istorijskoj gra|i. Urednik: akademik Paula Putanov. Izdavač: SRPSKA AKADEMIJA NAUKA I UMETNOSTI – OGRANAK AKADEMIJE (COBISS.SR-ID 258339335), Novi Sad 2010, str. 203-232.
Prof. Mihajlo B. SpasicPresident of the
Serbian Biochemical Society
7
7
Signalling Networks in Cancer
David R. Jones*
*Cancer Research UK Inositide Laboratory, The Paterson Institute for Cancer Research , The University of Manchester, Manchester, UK.
Abstract
Cancer is a complex disease. It requires multiple components in multiple regulatory systems to fail before the disease manifests. Cancer heterogeneity is clearly apparent as over 200 types of cancers have been documented. In the UK approximately 25% of people die from cancer. Cancers of the lung, colorectum, breast and prostate account for 47% of cancer deaths. 76% of cancer deaths occur in people aged 65 years old. Six common traits “hallmarks” of cancer have been identified: (1) cancer cells stimulate their own growth; (2) they resist inhibitory signals that might otherwise stop their growth; (3) they resist their own programmed cell death (apoptosis); (4) they stimulate the growth of blood vessels to supply nutrients to tumors (angiogenesis); (5) they can multiply forever; and (6) they invade local tissue and spread to distant sites (metastasis). In short, the hallmarks are distinctive and complementary capabilities that enable tumour growth and metastatic dissemination. These have provided us with a solid foundation for our current understanding of the biology of cancer. Recent advances in technology over the last two decades have identified four more hallmarks: (7) abnormal metabolic pathways; (8) evading the immune system; (9) chromosome abnormalities and unstable DNA; and (10) inflammation. Unfortunately, due to time constraints the focus of my lecture will only consider one of these hallmarks; how cancer cells have re-programmed their metabolic pathways.
Alterations in cell metabolism associated with cancer may be selected by cancer cells to meet the distinct metabolic needs of high cell proliferation rates. Unlike metabolism in differentiated cells, which is geared to efficient ATP generation, the metabolism in cancer cells must be adapted to facillitate the accumulation of biomass. Cancer cells divert a larger fraction of their nutrient metabolism to pathways other than mitochondrial respiration regardless of oxygen availability. The reprogramming of metabolic pathways in cancer cells is under the control of both oncogenes and tumor suppressors, many of which are downstream of signal transduction pathways involving phosphoinositide metabolism. In order to integrate a vast array of incoming signalling information into downstream cellular responses, a number of effector proteins rely on a master switch; the evolutionary conserved target of rapamycin (TOR) which is present in all eukaryotes. The mammlian TOR (mTOR) is a serine/threonine protein kinase which has been the focus of a multitude of research studies. Understanding more about phosphoinositide metabolism, mTOR regulation and cancer cell metabolomics together with help from metabolic imaging technology and computation of metabolic networks will enable us to design new therapeutic approaches to target cancer-specific metabolic pathways.
1
Proceedings
Marija Gavrovi}-Jankulovi}Immediate hypersensitivity: Molecular and immunological features of allergens 11
Djordje Miljkovi}Neuroinflammation: From Rat to Man 21
Ivan Spasojevi}Iron chelation: way to the hell and back 35
Du{ko P. Blagojevi}Molecular mechanisms of redox signalling in homeostasis, adaptations and pathology hypothermia 51
Sne`ana Dragovi}Biomonitoring for Human and Environmental Health: Current Status and Perspectives in Radioecology 61
Sne`ana D. Markovi} The effects of nitric oxide donors and the other bioactive substances on the energy and oxidative-antioxidative metabolism of blood cells and cancer cell lines 77
Karmen M. StankovMitochondrial redox metabolism in oxyphilic thyroid cancer 91
Jelena Ba{i} Matrix metalloproteinase-9, TNF alpha- and TNF receptor gene polymorphisms in juvenile idiopathic arthritis 101
11
11
12 13
12 13
14 15
14 15
16 17
16 17
18 19
18 19
20 21
20 21
22 23
22 23
24 25
of an adjuvant.
24 25
26 27
26 27
28 29
28 29
30 31
30 31
32 33
32 33
35
35
36 37
36 37
38 39
38 39
40 41
40 41
42 43
42 43
44 45
44 45
46 47
46 47
48 49
48 49
51
52 53
52 53
54 55
54 55
56 57
56 57
58 59
58 59
61
62 63
occurring
measuring
prophylactic
62 63
64 65
demonstrated
64 65
66 67
66 67
68 69
variety
68 69
analysed
70 71
70 71
72 73
72 73
74 75
74 75
77
78 79
78 79
80 81
80 81
82 83
82 83
84 85
84 85
86 87
86 87
88 89
88 89
90 91
90 91
92 93
92 93
94 95
were
94 95
AA
96 97
96 97
98 99
98 99
100 101
100 101
102 103
102 103
104 105
104 105
106 107
106 107
108 109
108 109
110
